Measuring out-of-field dose to the hippocampus in common radiotherapy indications.
Hippocampus
Out-of-field-dose
Radiotherapy
Thermoluminescent dosimetry
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
07 Apr 2023
07 Apr 2023
Historique:
received:
24
08
2022
accepted:
06
03
2023
medline:
11
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
The high susceptibility of the hippocampus region to radiation injury is likely the causal factor of neurocognitive dysfunctions after exposure to ionizing radiation. Repetitive exposures with even low doses have been shown to impact adult neurogenesis and induce neuroinflammation. We address the question whether the out-of-field doses during radiotherapy of common tumour entities may pose a risk for the neuronal stem cell compartment in the hippocampus. The dose to the hippocampus was determined for a single fraction according to different treatment plans for the selected tumor entities: Point dose measurements were performed in an anthropomorphic Alderson phantom and the out-of-field dose to the hippocampus was measured using thermoluminescence dosimeters. For carcinomas in the head and neck region the dose exposure to the hippocampal region for a single fraction ranged from to 37.4 to 154.8 mGy. The hippocampal dose was clearly different for naso-, oro- and hypopharynx, with maximal values for nasopharynx carcinoma. In contrast, hippocampal dose levels for breast and prostate cancer ranged between 2.7 and 4.1 mGy, and therefore significantly exceeded the background irradiation level. The mean dose to hippocampus for treatment of carcinomas in the head and neck region is high enough to reduce neurocognitive functions. In addition, care must be taken regarding the out of field doses. The mean dose is mainly related to scattering effects, as is confirmed by the data from breast or prostate treatments, with a very different geometrical set-up but similar dosimetric results.
Sections du résumé
BACKGROUND
BACKGROUND
The high susceptibility of the hippocampus region to radiation injury is likely the causal factor of neurocognitive dysfunctions after exposure to ionizing radiation. Repetitive exposures with even low doses have been shown to impact adult neurogenesis and induce neuroinflammation. We address the question whether the out-of-field doses during radiotherapy of common tumour entities may pose a risk for the neuronal stem cell compartment in the hippocampus.
METHODS
METHODS
The dose to the hippocampus was determined for a single fraction according to different treatment plans for the selected tumor entities: Point dose measurements were performed in an anthropomorphic Alderson phantom and the out-of-field dose to the hippocampus was measured using thermoluminescence dosimeters.
RESULTS
RESULTS
For carcinomas in the head and neck region the dose exposure to the hippocampal region for a single fraction ranged from to 37.4 to 154.8 mGy. The hippocampal dose was clearly different for naso-, oro- and hypopharynx, with maximal values for nasopharynx carcinoma. In contrast, hippocampal dose levels for breast and prostate cancer ranged between 2.7 and 4.1 mGy, and therefore significantly exceeded the background irradiation level.
CONCLUSION
CONCLUSIONS
The mean dose to hippocampus for treatment of carcinomas in the head and neck region is high enough to reduce neurocognitive functions. In addition, care must be taken regarding the out of field doses. The mean dose is mainly related to scattering effects, as is confirmed by the data from breast or prostate treatments, with a very different geometrical set-up but similar dosimetric results.
Identifiants
pubmed: 37029409
doi: 10.1186/s13014-023-02242-3
pii: 10.1186/s13014-023-02242-3
pmc: PMC10080875
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
64Informations de copyright
© 2023. The Author(s).
Références
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1458-64
pubmed: 20950947
Front Oncol. 2021 Feb 26;11:628007
pubmed: 33718201
Radiother Oncol. 2018 Jul;128(1):37-43
pubmed: 29548560
PLoS One. 2019 Jan 8;14(1):e0210069
pubmed: 30620742
J Clin Oncol. 2014 Dec 1;32(34):3810-6
pubmed: 25349290
Phys Med. 2017 Oct;42:239-246
pubmed: 28392312
Nat Rev Cancer. 2009 Feb;9(2):134-42
pubmed: 19148183
Sci Rep. 2017 Oct 31;7(1):14697
pubmed: 29089622
Clin Transl Radiat Oncol. 2020 Sep 12;25:52-60
pubmed: 33024844
Radiat Oncol. 2012 Nov 29;7:202
pubmed: 23193977
Phys Med. 2016 Mar;32(3):474-8
pubmed: 27053450
Med Phys. 2013 Oct;40(10):101706
pubmed: 24089896
Br J Radiol. 2014 May;87(1037):20130474
pubmed: 24620838
Exp Oncol. 2019 Mar;41(1):46-52
pubmed: 30932414
Radiother Oncol. 2015 Feb;114(2):230-8
pubmed: 25701297
Med Phys. 2020 Sep;47(9):4616-4625
pubmed: 32583441
Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):913-9
pubmed: 24456996
Radiother Oncol. 2014 Mar;110(3):416-21
pubmed: 23953411
PLoS One. 2014 Feb 28;9(2):e90007
pubmed: 24587184
Radiat Oncol. 2014 Nov 26;9:250
pubmed: 25424536
Phys Med Biol. 2014 Jul 7;59(13):N113-28
pubmed: 24925858
PLoS One. 2015 Mar 17;10(3):e0120141
pubmed: 25781636
Int J Radiat Oncol Biol Phys. 2021 Dec 1;111(5):1262-1275
pubmed: 34280471
Sci Rep. 2018 Apr 4;8(1):5595
pubmed: 29618828
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S10-9
pubmed: 20171502
Front Neurosci. 2011 Apr 21;5:59
pubmed: 21541259
Rep Pract Oncol Radiother. 2020 Mar-Apr;25(2):187-192
pubmed: 32021575
Cancer. 2005 Sep 15;104(6):1129-37
pubmed: 16080176
Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12822-7
pubmed: 23858442
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1537-46
pubmed: 18513883
Phys Med Biol. 2010 Dec 7;55(23):6999-7008
pubmed: 21076191
Radiat Oncol. 2018 Feb 20;13(1):29
pubmed: 29463267
J Proteome Res. 2015 May 1;14(5):2055-64
pubmed: 25807253
Radiat Oncol. 2015 Dec 10;10:253
pubmed: 26654128
Cancer Radiother. 2017 Aug;21(5):345-351
pubmed: 28433589
Radiother Oncol. 2019 Aug;137:45-54
pubmed: 31063923
Sci Rep. 2017 Jun 13;7(1):3443
pubmed: 28611367
Nat Rev Cancer. 2011 Apr;11(4):239-53
pubmed: 21430696
Med Dosim. 2017 Winter;42(4):310-316
pubmed: 28760560
J Appl Clin Med Phys. 2013 Mar 04;14(2):4139
pubmed: 23470942
Quant Imaging Med Surg. 2018 Oct;8(9):902-909
pubmed: 30505719